ClinicalTrials.gg
CompletedNCT04894071Updated Jan 14, 2022

QA102 Phase 1 Study in Healthy Young and Older Adult Subjects

A Phase 1 interventional study of QA102 and Placebo in Age-related Macular Degeneration, sponsored by Smilebiotek Zhuhai Limited. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-14.

Sponsored by Smilebiotek Zhuhai Limited · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Nov 2021, 5 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.

Enrollment
209th of 491
69 · median 55
Started
2021
with 27 others
Phase 1
91 of 645
10 open now
Registered
481st of 645
by date

Among the 645 studies in Macular Degeneration with a site in United States, this one is the 209th largest by enrollment of the 491 interventional ones that give a count, is one of 28 that started in 2021, is one of 91 in phase 1, and was the 481st registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:

79 more — sign in →

All 84 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Macular Degeneration with a site in United States, or all of them as a file.
02

Study summary

This will be a double masked, randomized, placebo controlled, single and multiple oral dose study conducted in 3 parts. The safety and tolerability of single and multiple ascending oral doses of QA102 in healthy young and older adult subjects will be evaluated. The study will also characterize the pharmacokinetic (PK) profile of QA102 in plasma and urine after single and multiple oral doses of QA102. Besides, the metabolite profile of QA102 will also be characterized.

Part 1 will comprise a single dose, sequential cohort design. Part 2 will comprise a multiple dose, sequential cohort study. Part 3 will comprise a multiple dose, single cohort study in older subjects.

03

Conditions studied

  • Age-related Macular Degeneration
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. between 18.0 and 32.0 kg/m2, inclusive.
  2. In good health, determined by no findings from medical history, physical examination, visual acuity testing, 12 lead , vital signs measurements, and clinical laboratory evaluations at screening and check in as assessed by the investigator or designee.
  3. Females of nonchildbearing potential defined as permanently sterile or . Males will agree to use .
  4. Able to comprehend and willing to sign an ICF and to abide by the study restrictions.
  5. Young (between 18 and 59 years of age, for Part 1 and 2) or Older (between 60 and 75 years of age, for Part 3) males or females of nonchildbearing potential, of any race, inclusive, at screening.

Exclusion criteria

Exclusion Criteria:

  1. Subject is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
  2. Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator (or designee).
  3. History of significant , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the investigator (or designee).
  4. Active or recent (within 30 days of screening) infection or history of recurrent chronic infections with underlying condition that may predispose one to infections. Viral infections with symptoms resolved will be allowed up to 14 days prior to check-in.
  5. History of of any type, other than surgically excised non-melanomatous skin cancers or in situ cervical cancer within 5 years before check-in.
  6. Female subjects (surgically sterile females only) with a positive pregnancy test at screening or check in or who are lactating.
  7. History of alcoholism or drug/chemical abuse within 2 years prior to check in.
  8. Positive urine drug or alcohol results at screening or check in.
  9. Participation in a clinical study involving administration of an drug (new chemical entity) in the past 30 days or 5 half-lives (whichever is longer) prior to dosing.
  10. Consumption of alcohol from 48 hours prior to check-in.
  11. Administration of any vaccine, including a Coronavirus Disease 2019 vaccine, within the past 30 days prior to dosing.
  12. Subjects who, in the opinion of the investigator (or designee), should not participate in this study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    QA102 group

    Drug: QA102

  • Placebo comparator
    Placebo group

    Drug: Placebo

Interventions

  • DrugQA102

    Intervention of Part 1: 6 dose levels (50mg, 100mg, 200mg, 400mg, 800mg, 1600mg of QA102 capsules), oral administration, single dose. Intervention of Part 2: 2 dose levels (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 1 of the study), oral administration. Intervention of Part 3: 1 dose level (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 2 of the study), oral administration.

  • DrugPlacebo

    Intervention of Part 1: 6 dose levels (50mg, 100mg, 200mg, 400mg, 800mg, 1600mg of Placebo capsules), oral administration, single dose. Intervention of Part 2: 2 dose levels (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 1 of the study), oral administration. Intervention of Part 3: 1 dose level (the dose levels, dosing frequency and dosing duration will be decided on the basis of data from Part 2 of the study), oral administration.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of Adverse Events

    To evaluate the safety and tolerability of single and multiple ascending oral doses of QA102 in healthy young adult and elderly subjects.

    Time frame: Up to 7 days after dosing

Secondary outcomes

  1. Area under the plasma concentration-time curve (AUC) from time zero to 12 hours postdose [AUC0-12]

    Time frame: up to 12 hours postdose

  2. Maximum observed plasma concentration [Cmax]

    Time frame: Up to 48 hours postdose

  3. time of the maximum observed plasma concentration [tmax]

    Time frame: up to 48 hours postdose

Other outcomes

  1. renal clearance (CLR )

    Time frame: up to 24 hours postdose

  2. Metabolite characterization of QA102

    To characterize metabolites of QA102 in plasma samples after multiple oral doses of QA102 in healthy adult subjects.

    Time frame: Within 24 hours after last dose

07

Study locations

1 site
  • Covance Clinical Research Unit Inc.
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Nov 2021, 5 months.

Of 60 industry-sponsored phase 1 interventional studies under Macular Degeneration, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 27. This study's 5 months is below that.

Counting every sponsor, half of 75 studies reached it within 18 months; a quarter within 10 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2021
First posted
May 20, 2021
StartActual
May 17, 2021
Primary completionActual
Nov 15, 2021
CompletionActual
Nov 15, 2021
Last update
Jan 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04894071
Lead sponsor
Smilebiotek Zhuhai Limited
Responsible party
Sponsor
First posted
May 20, 2021
Start date
May 17, 2021
Primary completion
Nov 15, 2021
Completion
Nov 15, 2021
Last update
Jan 14, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion